Background: Prior studies of the Medicare Part D coverage gap are limited in generalizability and scope.
H
ypertension and hyperlipidemia affect 65 million and 76 million Americans, respectively, most of whom are aged 65 years or older (1) . Both asymptomatic conditions are risk factors for coronary heart disease, stroke, and other cardiovascular diseases (1) . Although effective drug therapies have helped reduce cardiovascular deaths, these benefits have not reached many older patients because of low use of and adherence to these drugs, often due to cost and lack of prescription coverage (2-4).
Medicare Part D was implemented on 1 January 2006 to reduce such barriers and facilitate access to medications by offering voluntary prescription coverage to Medicare beneficiaries. However, the standard Part D design included a coverage gap, wherein beneficiaries had to pay 100% of drug costs after total drug spending exceeded an annual threshold ($2250 in 2006) . After total annual drug spending exceeded the catastrophic coverage threshold ($5100 in 2006), they exited the coverage gap and paid 5% of drug costs. Some higher-premium Part D plans offered generic-only or both brand-name and generic drug coverage during the gap, but only a small proportion of beneficiaries enrolled in such plans (11% in 2006). The Patient Protection and Affordable Care Act of 2010 has proposed to gradually phase in subsidies for brand-name and generic drugs during the gap over 10 years. Hence, most elderly persons will continue to face some coverage gap until its planned closure in 2020 (5) .
How coverage gap entry affects medication use in elderly persons with asymptomatic cardiovascular conditions, such as hypertension and hyperlipidemia, is not wellunderstood. Do they decrease their use of antihypertensive or lipid-lowering agents or switch to less expensive alternatives? Do they maintain medications (for example, pain relievers) for symptomatic conditions but not for clinically important but asymptomatic cardiovascular conditions? Does effect vary by type of coverage in the gap? Previous studies have found that entering the coverage gap reduces medication use (6 -14) , but few have evaluated diseasespecific cohorts (both studies that did so examined patients with diabetes) (6, 14) or effect by type of coverage in the gap (6, 13, 14) . None evaluated how patient behavior might differ for medications for symptomatic versus asymptomatic conditions. Furthermore, study findings are not generalizable because the data come from 1 or 2 retail pharmacy chains (7, 10, 12, 14) , surveys (8, 9) , or regional Medicare Advantage (managed care) plans (6, 8, 9, 11, 13) . Thus, the effects of the coverage gap and type of gap coverage are largely unknown among three quarters of the at least 20 million standalone Part D plan enrollees, many with hypertension and hyperlipidemia.
To our knowledge, this study is the first to empirically examine the effect of the Part D coverage gap on the use of antihypertensive and lipid-lowering medications (overall and by brand-name or generic status) and drugs for common symptomatic conditions (acid suppressants, pain relievers, and antidepressants) in nationally representative samples of fee-for-service Medicare beneficiaries with hypertension and hyperlipidemia. The study was approved by the University of Pennsylvania Institutional Review Board.
METHODS

Data Source
The study used Medicare inpatient, outpatient, and carrier claims files from 2005 and 2006 for a 5% random sample of Medicare beneficiaries. These files were linked to the 2006 Medicare Part D prescription drug event file, a personal summary file with demographic and enrollment information, and a Part D plan characteristics file.
Study Design and Sample
Using a quasi-experimental design, we compared drug use before and during the coverage gap in 2006 for beneficiaries who entered the coverage gap phase with that in a contemporaneous control group (15, 16). The months spent in catastrophic coverage-for patients (12% to 13%) whose total annual drug spending exceeded $5100 -were not included during the coverage gap analysis.
The study sampling frame consisted of beneficiaries who were aged 65 years or older in 2005, continuously covered under fee-for-service Medicare from 1 January Within each of the hypertension and hyperlipidemia samples, we created 3 groups of patients ineligible for lowincome subsidies (LISs) who entered the coverage gap phase during 2006 and had no coverage (100% cost sharing for any drug), generic-only coverage (100% cost sharing for only brand-name drugs), or brand-name and generic coverage (no change in cost sharing for any drug) (non-LIS). For the contemporaneous control group, we selected beneficiaries whose total annual drug spending exceeded the coverage gap threshold ($2250) but who were not subject to increased payments during the coverage gap because they were fully eligible for the LIS (full LIS).
Outcome Measures
We measured the use of antihypertensive and lipidlowering medications (Appendix Table 1 , available at www .annals.org) by using 3 outcomes: number of 30-day supplyequivalent prescriptions available per month, medication adherence, and continuous medication gaps. We identified the monthly number of 30-day supply-equivalent prescriptions for antihypertensives or lipid-lowering medications (both overall and by brand-name or generic status) that was available to a patient in each month in the periods before and during the coverage gap as follows. We spread the reported days' supply from each prescription from the dispensing date to the date the prescription would have been exhausted and then divided the cumulative days' supply available in each month by the number of days in the month. This ensured that we accounted for use of multiple medications. We estimated medication adherence by using the proportion of days covered, which we calculated by dividing the number of days with drug supply from at least 1 antihypertensive (or lipid-lowering) prescription available by the number of days in the period (17) . We defined patients with a proportion of days covered less than 0.80 as 
Contribution
For drugs used to treat hypertension and hyperlipidemia, Part D beneficiaries with no gap coverage or generic-only gap coverage were less likely to fill prescriptions, had more continuous medication gaps, and were less likely to adhere to appropriate medication schedules than those without a coverage gap. Patient behavior varied less by type of plan for drugs used to treat symptomatic conditions.
Caution
This was an observational study based on administrative data.
Implication
The Part D coverage gap is associated with decreased use of effective medications for serious conditions.
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Original Research nonadherent (18, 19) . We measured any continuous medication gap to indicate whether the patient had at least 1 continuous episode with no supply of antihypertensive (or lipid-lowering) medications for 30 days or more (20) . For this analysis, we limited the sample to patients with at least 2 months in both the periods before and during the coverage gap (about 80% in both disease samples) to ensure that we had sufficient time to observe continuous 30-day gaps in each period. We examined the use of 3 a priori-selected drug classes (acid suppressants, pain relievers, and antidepressants [Appendix Table 1 ]) for symptomatic conditions by using the monthly number of 30-day supply-equivalent prescriptions available, as described earlier. All outcomes allowed drug supply to carry over from month to month, and the excess days' supply in the last month of the observation period was truncated. We excluded monthly observations from January 2006 because drug supply is underestimated owing to the unavailability of patients' drug use in 2005.
Covariates
Covariates included age, sex, race and ethnicity, Medicare entitlement status, metropolitan status (urban or ru- CHD ϭ coronary heart disease; ESRD ϭ end-stage renal disease; IQRϭ interquartile range; LIS ϭ low-income subsidy; NA ϭ not applicable; RxHCC ϭ prescription drug hierarchical condition category. * Medicare entitlement due to ESRD. † Modified RxHCC score wherein coefficients for age and sex are zeroed out in the score calculation because regression models separately control for these variables. ‡ Defined as a county with Ն25% adults without a high school diploma.
Original Research Effect of Medicare Part D Coverage Gap on Medication Use ral), census region, area-level characteristics (per capita income, unemployment rate, education level) in beneficiary's county of residence, and prescription drug hierarchical condition category risk score. This score predicts each beneficiary's total drug spending in the subsequent year on the basis of 197 medical conditions recorded in his or her Medicare claims from the previous year (21).
Statistical Analysis
We estimated the effect of the coverage gap on the monthly number of 30-day supply prescriptions available and monthly adherence with segmented regression models that used generalized estimating equations with first-order, autoregressive correlation structure. Segmented regression models estimate changes in monthly outcomes from 1 segment of time to the next. We defined 2 time segments: the pregap period (February 2006 to 1 month before coverage gap entry) and the during-gap period (the month of coverage gap entry to 1 month before catastrophic coverage entry or December 2006, whichever came earlier). The models included interactions between study groups, cover- Month 0 represents the calendar month of entry into the coverage gap. The figures are based on mean differences in adjusted 30-day supply prescriptions available per month for each study group relative to the control group of fully eligible low-income subsidy patients. The adjusted 30-day supply prescriptions used per month were estimated with segmented regression models using generalized estimating equations with first-order, autoregressive correlation structure; variables for study groups, coverage gap status, months, and months after entering coverage gap; and interaction terms between group indicators and time-related variables. age gap status, months, and months after entering the coverage gap so that we could examine the temporal dynamics in use among the 3 study groups relative to the control group while allowing each group its own temporal profile. We calculated percentage of changes in the monthly number of 30-day supply prescriptions due to the coverage gap for each non-LIS study group as the absolute change in their monthly number of prescriptions attributable to the coverage gap, divided by their expected use in the coverage gap as estimated from the segmented regression coefficients. In addition, we used a 2-period, difference-indifferences logistic regression models with the generalized estimating equation method to estimate changes in the odds of nonadherence or having a continuous medication gap before and after patients entered the coverage gap. We performed sensitivity analyses to test the robustness of study findings. We repeated all analyses by using propensity scores estimated with a generalized logit model involving all preceding covariates (22, 23) . We also repeated all analyses by using within-person fixed-effects models, which account for time-stable unobserved differences between comparison groups. In addition, we included control variables for the month of coverage gap entry and number of months in the gap. Sensitivity analyses used different sample inclusion criteria related to hypertension (or hyperlipidemia) diagnoses (Ն1 inpatient or outpatient claim vs. Ն1 inpatient claim or Ն2 outpatient claims) and follow-up time available before and during the coverage gap (2 months vs. 4 months) to examine continuous medication gaps.
We conducted subgroup analyses in patients with and without high risk for future cardiovascular events (that is, patients with coronary heart disease, diabetes, or cerebrovascular disease). In addition, because 2 lipid-lowering drugs (simvastatin and pravastatin) became available as generic drugs during the study period, we conducted subgroup analyses in patients with hyperlipidemia who did and did not use these products before coverage gap entry. All statistical analyses were performed by using Stata, version 11.1 (StataCorp, College Station, Texas).
Role of the Funding Source
This study was supported by Pfizer and the American Heart Association. The funding sources had no role in the design, conduct, or analysis of the study or in the decision to submit the final manuscript for publication.
RESULTS
Overall, 46% (hypertension) and 47% (hyperlipidemia) of Part D plan enrollees had total drug spending exceeding the coverage gap threshold in 2006 (Appendix Figure 1 , available at www.annals.org). Table 1 shows characteristics of the 3 non-LIS study groups and the LIS control group for the hypertension and hyperlipidemia samples. The mean number of monthly prescriptions for antihypertensives (1.53 to 1.60) and lipid-lowering medications (0.73 to 0.78) before coverage gap entry was similar across the groups ( Table 1) . Before coverage gap entry, all 3 non-LIS groups had similar out-of-pocket costs, paying an average of $16 to $17 per antihypertensive prescription Table  2 , available at www.annals.org). This translated into relative decreases of 4.8% and 7.2% in the monthly number of antihypertensive and lipid-lowering prescriptions per patient during the coverage gap, respectively (Appendix Table 3, available at www.annals.org). Compared with the control group, patients with no gap coverage had a statistically significant decrease in brand-name and generic prescriptions for both drug classes. Patients with generic-only gap coverage had fewer brand-name prescriptions but no statistically significant change in generic prescriptions for either drug class; hence, overall use decreased during the gap period. Patients with brand-name and generic gap coverage had no statistically significant decrease in use of either drug class after coverage gap entry compared with control patients. Similarly, monthly adherence decreased for patients with no gap coverage and generic-only gap coverage compared with control patients (Appendix Figure  3 and Appendix Table 4 , available at www.annals.org).
The likelihood of nonadherence or having continuous medication gaps increased during the coverage gap for patients with no gap coverage and generic-only gap coverage compared with the control group ( Table 2 ). For instance, among patients with hyperlipidemia and no gap coverage, the absolute increase in the proportion of patients with continuous medication gaps was 10.9% after gap entry compared with an absolute increase of only 3.6% in the control group (odds ratio, Subgroup analyses in patients with and without coronary heart disease, diabetes, or cerebrovascular disease found similar effects of the coverage gap across all groups and outcomes (Appendix Table 5 , available at www.annals .org). The subgroup analyses in patients with and without use of lipid-lowering drugs that went off patent in 2006 also found similar effects on patients with no gap coverage. However, compared with the control group, patients with generic-only gap coverage who used pravastatin or simvastatin before coverage gap entry experienced no changes, whereas those using other lipid-lowering medications had statistically significant increases in nonadherence and continuous medication gaps. Figure 2 shows that for drugs for symptomatic conditions, patients with no gap coverage had a larger decrease in use of acid suppressants (8.6% and 6.9% relative decreases in the hypertension and hyperlipidemia samples, respectively) than the control group (Appendix Tables 6 and 7, available at www.annals.org). Use of pain relievers and antidepressants also decreased in the coverage gap, but the effect was smaller. The coverage gap did not affect use of drugs in these 3 classes in patients with generic-only coverage and patients with brand-name and generic coverage when compared with control patients.
Sensitivity analysis results from fixed-effects models and those using more restrictive sample inclusion criteria resulted in estimates in the same direction but slightly higher in magnitude than our main findings. Results from all other sensitivity analyses showed estimates similar in direction and magnitude to our main findings.
DISCUSSION
We found that the Part D coverage gap was associated with fewer monthly prescriptions and a higher likelihood of nonadherence and continuous medication gaps for antihypertensive and lipid-lowering drugs among patients with hypertension and hyperlipidemia who had no gap coverage and generic-only gap coverage. Of greater concern was a similar finding of increases in nonadherence and medication gaps in subgroups of patients at higher risk for future cardiovascular events. Our study did not evaluate the effect of reduced adherence on clinical outcomes. However, another study of Medicare patients with similar baseline adherence as ours for antihypertensives (85%) and lipid-lowering agents (73%) found worse physiologic outcomes, higher rates of nonelective hospitalizations and emergency department visits, and increased mortality associated with even lower levels of nonadherence than those identified in our study (18) . Although the motivation for designing the coverage gap was to limit the projected cost of the Part D program and increase the likelihood of passage of the Part D legislation, these findings suggest that other Medicare program costs may increase if continued decreases in adherence worsen health outcomes and increase use of other medical services. Under the recent health care reform legislation, the coverage gap is to be phased out gradually over the next decade; however, patient out-of-pocket liability in the coverage gap will continue to increase, exceeding $6000 in 2020 (vs. $2850 in 2006) (5) . Thus, the proposed gradual phase-out may be too little and come too late for many elderly Medicare beneficiaries with these cardiovascular conditions. In the interim, a multifactorial approach by all stakeholders involved, including clinicians, pharmacists, health plans, and government agencies, should be used to help patients identify and adopt lower-cost alternatives for cardiovascular medications to maintain adherence.
As in 2 previous studies (both in patients with diabetes) (6, 14) , we found that generic-only gap coverage conferred limited advantage relative to no gap coverage. Our finding that decreases in brand-name prescriptions were not offset by increases in generic prescriptions may be due to a lack of generic versions of some drugs, a lack of patient knowledge or willingness to switch to generic or therapeutic substitutes, or the hassle involved in getting a prescription changed. However, unlike previous studies, we conducted a subgroup analysis that found that among patients with hyperlipidemia with generic-only gap coverage who used pravastatin or simvastatin (which became generic in early to mid-2006) before gap entry, overall lipid-lowering medication use did not decrease during the gap. The subgroup receiving other (primarily brand-name only) statins did decrease overall use of lipid-lowering drugs. Because several brand-name cardiovascular medications will go off patent in the next 3 years (24), it may be beneficial for patients receiving these medications to enroll in plans offering generic-only gap coverage, especially because the average monthly premiums are not substantially higher ($17 to $60 higher in 2010) than in similar plans with no gap coverage (25) .
Another novel finding was the lower to no significant decrease in pain reliever and antidepressant use compared with cardiovascular medications in patients with no gap coverage and generic-only gap coverage. This suggests that patients may be more likely to maintain medications that enhance daily functioning and comfort at the risk of exacerbating more distant comorbid conditions associated with clinically important but asymptomatic conditions. Thus, it is important that clinicians and pharmacists counsel patients who are expected to enter or are already in the coverage gap.
In contrast, the larger decreases in acid suppressant use might reflect that acid suppressants are overprescribed for minor symptoms (26 -30) , patients can modify their lifestyle to rely less on acid suppressants, and over-the-counter substitutes for several acid suppressants are available. Hence, patients with no gap coverage may have been more likely to stop these medications when faced with the prospect of paying their full cost (31) . Acid suppressant use did not decrease in patients with generic-only or brand-name and generic gap coverage. Some of these patients probably continued discretionary use of acid suppressants given the availability of coverage in the gap (32) . This finding suggests that phasing out the coverage gap under health care reform may also increase spending on medications with low clinical value. Hence, more clinically nuanced costsharing policies, such as those based on the principles of value-based insurance design, may be needed to provide incentives for use and adherence to high-value medications while discouraging overuse of products with low marginal benefit (33) . The current approach to closing the coverage gap, which requires 25% cost sharing for all medications regardless of therapeutic benefit, does not address this need.
We believe our findings are valid and robust despite several limitations inherent in an observational study. First, we used data on prescription refills as a proxy for medication use and adherence; however, this approach has been validated (34, 35) . Second, although data on prescriptions filled outside of Part D were unavailable, this was unlikely to be an issue because discount stores did not start offering $4 monthly supplies for selected common generic drugs until late 2006. Third, because this was a nonrandomized study, it is important to determine whether the findings are attributable to the coverage gap or to unobserved differences between comparison groups. There are several reasons to believe the latter is not the case. The study required all patients to use a medication for their hypertension (or hyperlipidemia) before coverage gap entry and to have total drug spending greater than $2250. This ensures more homogenous comparison groups in terms of their medication needs. We also controlled for several covariates, including the prescription drug hierarchical condition category risk score-an important risk adjuster (36) . In addition, we did not compare the 3 coverage gap groups with each other because patients could self-select the types of gap coverage. Instead, we compared patients in each non-LIS group with patients in the LIS control group, none of whom was subject to increased payments during the coverage gap and most of whom had been randomly assigned to a Part D plan in 2006. Although the LIS control group differed from the study groups in several characteristics, the prepost, repeated-measures design and the 2-period analyses with contemporaneous comparison groups are validated
Original Research Effect of Medicare Part D Coverage Gap on Medication Use study designs that control for time-invariant differences between groups (15, 37). Our segmented regression models also indicated that the trend differences between study and control groups before the coverage gap were small. A final limitation was that we used 2006 data because they were the most recently available at the time of our analyses.
In conclusion, the Part D coverage gap worsened use of antihypertensive and lipid-lowering medications in patients with no gap coverage and generic-only gap coverage. If fully phased in, the coverage gap closure in 2020 will benefit such patients. However, in the intervening years, these patients will need help making optimal medication choices and maintaining medication adherence. Policymakers should consider Part D cost-sharing approaches and utilization management tools that reflect clinical and economic value and provide incentives for adherence to highly beneficial drugs while deterring use of drugs of low or questionable benefit. Month 0 represents the calendar month of entry into the coverage gap. The figures are based on mean differences in adjusted 30-day supply prescriptions available per month for each study group relative to the control group of fully eligible low-income subsidy patients. The adjusted 30-day supply prescriptions used per month were estimated with segmented regression models using generalized estimating equations with first-order, autoregressive correlation structure; variables for study groups, coverage gap status, months, and months after entering coverage gap; and interaction terms between group indicators and time-related variables. Data were adjusted for age, sex, race and ethnicity, Medicare entitlement status, metropolitan status (urban or rural), census region of residence, area-level characteristics (per capita income, unemployment rate, and education level) in beneficiary's county of residence, and prescription drug hierarchical condition category risk score. Error bars indicate 95% CIs obtained with 500 bootstrapped replicates. Error bars indicate 95% CIs. LIS ϭ low-income subsidy. * Percentage of change in the monthly number of 30-d supply prescriptions due to the coverage gap for each non-low-income subsidy study group was calculated as the absolute change in its monthly number of prescriptions attributable to the coverage gap divided by its expected use in the coverage gap estimated from the segmented regression coefficients. Segmented regression models used generalized estimating equations with first-order, autoregressive correlation structure; variables for study groups, coverage gap status, months, and months after entering coverage gap; and interaction terms between group indicators and time-related variables. Data are adjusted for age, sex, race and ethnicity, Medicare entitlement status, metropolitan status (urban or rural), census region of residence, area-level characteristics (per capita income, unemployment rate, and education level) in beneficiary's county of residence, and prescription drug hierarchical condition category risk score. Month 0 represents the calendar month of entry into the coverage gap. The figures are based on mean differences in adjusted monthly adherence rates for each study group relative to the control group of fully eligible low-income subsidy patients. The adjusted monthly adherence rates were estimated with segmented regression models using generalized estimating equations with first-order, autoregressive correlation structure; variables for study groups, coverage gap status, months, and months after entering coverage gap; and interaction terms between group indicators and timerelated variables. Data were adjusted for age, sex, race and ethnicity, Medicare entitlement status, metropolitan status (urban or rural), census region of residence, area-level characteristics (per capita income, unemployment rate, and education level) in beneficiary's county of residence, and prescription drug hierarchical condition category risk score. Error bars indicate 95% CIs obtained with 500 bootstrapped replicates.
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